Lung involvement in systemic sclerosis: Role of high resolution computed tomography and its relationship with other pulmonary and clinico-serological features

Journal of Biological Regulators and Homeostatic Agents

Volumn 28, Issue 3, 2014, Pages 481-488

  Colaci, M ^a   Sebastiani, M ^a   Manfredi, A ^a   Giuggioli, D ^a   Cassone, G ^a   Manzini, C U ^a   Ghizzoni, C ^a   Cerri, S ^a   Ferri, C ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

High resolution computed tomography; Lung fibrosis; Pulmonary arterial hypertension; Scleroderma; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; ANTINUCLEAR ANTIBODY;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RADIOLOGICAL PARAMETERS; RESPIRATORY TRACT PARAMETERS; RESPIROMETRY; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LUNG; LUNG DISEASE; MIDDLE AGED; RADIOGRAPHY;

ADULT; ANTIBODIES, ANTINUCLEAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84921891845     PISSN: 0393974X     EISSN: 17246083     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ferri C, Valentini G, Cozzi F, et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81:139-53.
2. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28:1573-6.
3. Steen VD. The lung in systemic sclerosis. J Clin Rheumatol 2005; 11:40-6.
4. Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology 2008; 47:59-61.
5. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
6. Walker KM, Pope J; Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group. Expert agreement on EULAR/EUSTAR-recommendations for the management of systemic sclerosis. J Rheumatol 2011; 38:1326-8.
7. Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Pölzleitner D, Burghuber OC, Tscholakoff D. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990; 176:755-9.
8. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur Resp J 1995; 8:492-506.
9. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Resp J 1993; 16:41-52.
10. Liang B-M, Lam DCL, Feng Y-L. Clinical applications of lung function tests: a revisit. Respirology 2012; 17:611-9.
11. Steele R, Hudson M, Lo E, Baron M. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012;64:519-24.
12. Gatta G, Di Grezia G, Iacomino A, Russo A, Petrillo M, Feragalli B, Cappabianca S, Grassi R. HRCT in systemic sclerosis: correlation between respiratory functional indexes and extension of lung failure. J Biol Regul Homeost Agents 2013; 27:579-87.
13. Vettori S, Cuomo G, Abignano G, Iudici M, Valentini G. Survival and death causes in 251 systemic sclerosis patients from a single Italian center. Reumatismo 2010; 62:202-9.
14. Walker JG, Pope J, Baron M, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007; 26:1401-9.
15. Toya SP, Tzelepis GE. The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 2009;29:861-8.
16. Launay D, Humbert M, Berezne A, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140:1016-24.
17. Khanna D, Tseng C-H, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63:3078-85.
18. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-15.
19. Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thor Imaging 2007;22:120-4.
20. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, Black CM, Coghlan JG. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43:461-6.
21. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimm Rev 2011; 10:248-55.